Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 47

1.

Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.

Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E.

J Clin Oncol. 2014 Dec 1;32(34):3848-57. doi: 10.1200/JCO.2014.56.9327. Epub 2014 Nov 3.

PMID:
25366688
[PubMed - indexed for MEDLINE]
2.

Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B.

BMC Cancer. 2012 Dec 22;12:616. doi: 10.1186/1471-2407-12-616.

PMID:
23259667
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B.

Breast Cancer Res. 2012 Aug 14;14(4):R117. doi: 10.1186/bcr3242.

PMID:
22889108
[PubMed - in process]
Free PMC Article
4.

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.

PMID:
22420423
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE.

PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249.

PMID:
21556366
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE.

PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062.

PMID:
18725978
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Medical students' cognitive and affective attitudes towards learning and using communication skills--a nationwide cross-sectional study.

Anvik T, Grimstad H, Baerheim A, Bernt Fasmer O, Gude T, Hjortdahl P, Holen A, Risberg T, Vaglum P.

Med Teach. 2008;30(3):272-9. doi: 10.1080/01421590701784356.

PMID:
18484454
[PubMed - indexed for MEDLINE]
8.

Curriculum factors influencing knowledge of communication skills among medical students.

Baerheim A, Hjortdahl P, Holen A, Anvik T, Fasmer OB, Grimstad H, Gude T, Risberg T, Vaglum P.

BMC Med Educ. 2007 Oct 10;7:35.

PMID:
17925041
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Assessing medical students' attitudes towards learning communication skills--which components of attitudes do we measure?

Anvik T, Gude T, Grimstad H, Baerheim A, Fasmer OB, Hjortdahl P, Holen A, Risberg T, Vaglum P.

BMC Med Educ. 2007 Mar 30;7:4.

PMID:
17394673
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.

Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6000-4.

PMID:
17062672
[PubMed - indexed for MEDLINE]
Free Article
11.

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J.

Eur J Cancer. 2006 Nov;42(17):2968-75. Epub 2006 Sep 11.

PMID:
16963261
[PubMed - indexed for MEDLINE]
12.

Comparing self-reported communication skills of medical students in traditional and integrated curricula: a nationwide study.

Gude T, Baerheim A, Holen A, Anvik T, Finset A, Grimstad H, Hjortdahl P, Risberg T, Vaglum P.

Patient Educ Couns. 2005 Sep;58(3):271-8.

PMID:
16061342
[PubMed - indexed for MEDLINE]
13.

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

Norum J, Risberg T, Olsen JA.

Ann Oncol. 2005 Jun;16(6):909-14. Epub 2005 Apr 22.

PMID:
15849222
[PubMed - indexed for MEDLINE]
Free Article
14.

[Should complementary therapies be offered in hospitals?].

Risberg T, Bremnes Y, Kolstad A, Holte H, Wist E, Mella O, Klepp O.

Tidsskr Nor Laegeforen. 2004 Dec 2;124(23):3078-80. Norwegian.

PMID:
15586193
[PubMed - indexed for MEDLINE]
Free Article
15.

Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.

Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I.

Acta Oncol. 2004;43(2):186-9.

PMID:
15163168
[PubMed - indexed for MEDLINE]
16.

Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer.

Wist EA, Sommer HH, Ostenstad B, Risberg T, Fjaestad K.

Acta Oncol. 2004;43(1):11-4.

PMID:
15068314
[PubMed - indexed for MEDLINE]
17.

Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway.

Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR.

Eur J Cancer. 2004 Mar;40(4):529-35.

PMID:
14962719
[PubMed - indexed for MEDLINE]
18.

Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway.

Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, Mella O, Wist E.

Support Care Cancer. 2004 May;12(5):312-8. Epub 2004 Feb 6.

PMID:
14767750
[PubMed - indexed for MEDLINE]
19.

Use of alternative medicine among Norwegian cancer patients is associated with mental distress--a follow-up study.

Risberg T, Kolstad A, Cassileth BR.

Acta Oncol. 2002;41(7-8):646-51.

PMID:
14651209
[PubMed - indexed for MEDLINE]
20.

[Should alternative therapists treat cancer--what is the opinion of oncology health personnel?].

Risberg T, Kolstad A, Wist EA, Holte H, Mella O, Klepp O.

Tidsskr Nor Laegeforen. 2003 Nov 6;123(21):3059-61. Norwegian.

PMID:
14618177
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk